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1. Introduction 
Thrombophilia (TF) is defined as an inherited or acquired tendency to develop thrombosis. 
TF creates a state of hypercoagulability, i.e. haemostasis activation without actual clot 
formation which can be detected in vitro by specific laboratory techniques. Thrombosis as a 
clinical phenomenon, however, only occurs when the balance between pro-coagulant and 
anti-coagulant elements of haemostasis is disrupted to such an extent that it leads to clot 
formation in the circulating blood.  
TF is most commonly associated with an increased risk of thrombosis in the venous system, 
i.e. venous thromboembolism (VTE). VTE is a common disease with an annual incidence of 
about 1 case per 1000 person-years and is a cause of substantial morbidity and mortality 
worldwide (White, 2003).  Furthermore, it is a chronic disease that often recurs. A third of 
patients with first VTE, experience a recurrence within the next 5 to 8 years. Recurrence is 
best prevented since it is fatal in 5 % of patients and late sequelae, such as post-thrombotic 
syndrome, are also very common (Schulman et al, 2006). The standard treatment for acute 
VTE (unfractionated or low-molecular-weight heparin, followed by vitamin K antagonists 
for at least several months) reduces the risk of recurrence by 80 to 90 % (Kearon et al, 2008). 
Although ideally all patients should receive long-term treatment with vitamin K antagonists 
to reduce the risk of recurrence, one has to bear in mind the 2 -3 % annual incidence of major 
bleeding on anticoagulant treatment (Ansell et al, 2008). The duration of anticoagulant 
treatment should therefore be tailored individually to optimize the preventive action of 
treatment with the minimum risk of bleeding. The likelihood of recurrence varies among 
individuals and is strongly influenced by the presence of clinical risk factors. Patients whose 
first VTE was triggered by a circumstantial risk factor (provoked VTE) have a lower risk of 
recurrence than patients whose event was unprovoked (idiopathic VTE), or who carry 
persistent risk factors (Kearon et al, 2008). It is, however, arguable whether the level of risk 
estimated from clinical risk factors alone justifies long-term anticoagulation.    
For a long time it was thought that screening for TF, a persistent risk factor for VTE, would 
facilitate clinical decision-making in determining the duration of anticoagulant treatment. 
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Over the past decades knowledge of TF has increased substantially, as did the number of 
individuals screened for TF. It was shown that when all known TF defects are considered, 
TF is found in about half of patients with the first VTE (Christiansen et al, 2005). However, 
routine TF screening is usually limited to those TF defects that carry a strong to moderate 
risk of VTE: antithrombin, protein C and protein S deficiencies, factor V Leiden, 
prothrombin G20210A mutation (inherited defects) and antiphospholipid antibodies 
(acquired defects). Testing for other TF defects, such as hyperhomocysteinaemia, high 
fibrinogen, increased factors VIII, IX, XI, dysfibrinogenaemia, reduced tissue factor pathway 
inhibitor and factor XIII polymorphisms is usually only performed in clinical studies 
(Stegnar, 2010). 
TF status does not directly translate into an increased risk of either first or recurrent VTE 
(Christiansen et al, 2005). First of all, there is considerable variation in the magnitude of risk 
associated with different TF defects. Furthermore, the magnitude of risk a specific TF defect 
carries is not the same for first or for recurrent VTE. The most common TF defects, such as 
factor V Leiden and prothrombin G2021A mutation, carry a modest risk of both first and 
recurrent VTE (Ho et al, 2006). The rarely occurring deficiencies of antithrombin, protein C 
and protein S, historically believed to be very strong risk factors for first VTE, convey only a 
slightly higher risk for recurrence than factor V Leiden and prothrombin G2021A mutation 
(Christiansen  et al, 2005; De Stefano et al, 2006).  
The results of TF screening actually alter the clinical management only in selected groups of 
VTE patients (Stegnar, 2010). Moreover, since VTE is a multi-causal disease, there are 
usually other factors apart from TF that contribute to the development of VTE (Rosendaal 
1999). It seems therefore that to assess VTE risk in individuals with TF an additional tool is 
needed. The aim of this article is to review the available evidence as to whether screening 
for hypercoagulability could represent such a tool.  
2. Activation of haemostasis  
The initial events in haemostasis involve activation of the endothelium and blood cells in 
response to vessel wall injury, which results in release of a variety of soluble factors 
involved in the control of haemostasis and cell adhesion. In this review, cell adhesion will be 
limited merely to cell adhesion molecules P-selectin, E-selectin, vascular cell adhesion 
molecule 1 (VCAM-1) and intercellular cell adhesion molecule 1 (ICAM-1) that mediate in 
the binding of endothelium and blood cells.  
Blood coagulation is initiated by the release of tissue factor from activated endothelial and 
blood cells. Activated endothelial cells and platelets express P-selectin, which binds 
monocytes and macrophages. Bound monocytes and macrophages expose tissue factor to 
the circulation. Tissue factor forms a complex with circulating activated factor VII. This 
complex activates factor X to activated factor X (Xa) and factor Xa converts minor quantities 
of prothrombin into thrombin. In this process, prothrombin fragments 1+2 (F1+2) are 
released. These events are regulated by tissue factor pathway inhibitor, which neutralizes 
factor Xa and by antithrombin, which inactivates thrombin by forming thrombin-
antithrombin (TAT) complexes. When the threshold level of thrombin is generated, 
thrombin activates platelets, as well as factors XIII, V, VIII and XI to augment its own 
generation. This is achieved by further conversion of factor X to factor Xa, using activated 
factors VIII and IX as cofactors. Factor Xa together with activated factor V (prothrombinase 
complex) converts the majority of prothrombin into thrombin. These events are regulated by 
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activated protein C and its cofactor protein S, which neutralize activated factors V and VIII 
and so limit thrombin generation (Monroe & Hoffman, 2006). 
Thrombin cleaves fibrinogen and fibrinopeptides A and B are released from alpha and beta 
polypeptide chains of fibrinogen. The resulting fibrin monomers polymerise to form soluble 
non-cross-linked fibrin, which is then cross-linked by activated factor XIII. The formation of 
fibrin triggers activation of the fibrinolytic system. Tissue-type plasminogen activator (t-
PA), which is released by endothelial cells, activates plasminogen to plasmin. Plasmin 
degrades fibrin to fibrin degradation products of various molecular sizes.  D-dimer, the 
smallest of the fibrin degradation products, retains the  cross-links of the original fibrin. 
These events are regulated by several inhibitors of fibrinolysis: plasminogen activator 
inhibitors type 1 and 2 (PAI-1 and PAI-2), antiplasmin and thrombin activatable fibrinolysis 
inhibitor (Rijken & Lijnen, 2009).  
3. Laboratory methods to detect activation of haemostasis  
Activation of haemostasis (hypercoagulability) is ideally detected prior to the appearance of 
thrombotic phenomena. Laboratory recognition of hypercoagulability is, however, a very 
demanding task due to the complexity of the haemostatic system. It can be detected by 
global tests (global haemostasis screening assays) that provide an overview of the entire 
haemostatic system, including enzymes, cofactors and inhibitors. Another approach to 
detecting hypercoagulability is to measure specific substances (peptides, enzymes, enzyme-
inhibitor complexes) that are liberated with activation of the coagulation and fibrinolysis 
systems in vivo (specific markers of haemostasis activation). The most recent method to 
assess hypercoagulability is to detect molecules that are released from activated endothelial 
and blood cells in response to injury of the vessel wall (markers of endothelial and platelet 
activation). 
3.1 Global haemostasis screening assays 
Activated partial thromboplastin time (aPTT) has been in use for more than half a century 
(Langdell et al, 1953). It is simple and the most widely used global haemostasis screening 
assay, sensitive to all coagulation factors except factor VII. The end-point of this assay is the 
formation of a fibrin clot, detected manually or automatically by measuring the optical 
density of plasma after addition of phospholipids and a surface activator such as celite. 
Clotting occurs when 3 – 5 % of the total amount of thrombin is produced (Brummel et al, 
2002) and therefore subsequent haemostatic responses or possible abnormalities of the 
haemostatic process cannot be observed (Mann et al, 2003). Nonetheless, a strong association 
was found between shortened aPTT and increased risk of first (Tripodi et al, 2004) and 
recurrent VTE (Hron et al, 2006; Legnani et al, 2006). The increase in VTE risk was 
independent of TF status. Shortening of aPTT might be due to increased concentrations of 
factors VIII, IX and XI  Legnani et al, 2006).  
Thromboelastography (TEG) monitors haemostasis as a dynamic process, evaluating both 
clotting, fibrinolysis and platelet function. TEG variables are derived from a trace produced 
from measurement of the viscoelastic changes associated with clot formation and 
degradation (Sorensen et al, 2003).   
Whilst the whole blood sample in a TEG cuvette remains liquid, the motion of the cuvette 
does not affect a pin which is suspended freely from a torsion wire. However, when the clot 
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starts to form, the fibrin strands “couple” the motion of the cup to the motion of the pin, 
which is amplified and recorded. Several variables of the recording can be evaluated such as 
the reaction time, angle formed by the slope of the TEG trace, maximum amplitude and clot 
lysis index (Mallet & Cox, 1992).   
TEG as a tool to measure hypercoagulability in the setting of VTE was only assessed in small 
studies. TEG showed a marked hypercoagulable profile in patients with acute VTE (Spiezia 
et al, 2008). Also in patients with a history of venous or arterial thrombosis, shorter clotting 
times and accelerated maximum velocity of clot propagation were measured (Hvitfeldt 
Poulsen et al, 2006). However, another study in patients with a history of cerebral vein 
thrombosis did not confirm these results (Koopman et al, 2009). TF, present in 
approximately half of the patients in these studies, did not influence TEG parameters. 
Similarly, in individuals with a personal or family history of VTE, hypercoagulable TEG was 
measured in 40 % of patients, but it did not correlate with TF status (O’Donnell et al, 2004). 
TEG therefore cannot be used as a screening test for TF, but it might be a useful adjunctive 
test, particularly in patients without known TF defects. Further studies are needed to 
determine whether TEG can be used to predict the recurrence of thrombotic events.   
However, TEG is poorly standardized, has a high coefficient of variation and is influenced 
by many pre-analytical variables, which makes it less suitable for routine clinical use to 
assess hypercoagulability (Chen & Teruya, 2009). Besides, it is a whole blood assay and 
therefore frozen-thawed samples cannot be used. 
Thrombin generation assay (TGA) reflects the potential of plasma to generate thrombin 
following in vitro activation of coagulation with tissue factor or other trigger (Hemker et al, 
2002). The thrombin concentration is continuously monitored by adding a suitable thrombin 
substrate and formation of split products is detected by optical densitometry or fluorometry. 
The resulting thrombin generation curve and its three most important parameters of lag 
time, peak value and area under the curve or endogenous thrombin potential, reflect and 
integrate all pro- and anticoagulant reactions that regulate the formation and inhibition of 
thrombin (van Veen et al, 2008). However, TGA does not measure the final step of 
coagulation, i.e. fibrin formation. TGA is performed in plasma, is commercially available 
and relatively easy to use. It is, however, not standardized; it is influenced by many pre-
analytical variables and there is a high inter-laboratory variability due to different reagents 
and their concentrations, making it difficult to establish reference ranges (Castoldi & Rosing 
2011).  
Thrombin generation is elevated in antithrombin deficiency (Wielders et al, 1997; Alhenc-
Gelas et al, 2010), protein S deficiency (Castoldi et al, 2010), protein C deficiency (Hezard et 
al, 2007), in carriers of factor V Leiden (Hezard et al, 2006; Lincz et al, 2006) and 
prothrombin G202010 mutation (Kyrle et al, 1998; Lavigne-Lissalde et al, 2010). It is also 
associated with the presence of antiphospholipid antibodies (Liestol et al, 2007; Devreese et 
al, 2009) and increased levels of factors VIII (ten Cate-Hoek et al, 2008), IX and XI 
(Siegemund et al, 2004). 
Elevated thrombin generation was also investigated as a risk factor for the first VTE event 
and its recurrence. It was shown that elevated thrombin generation was associated with a 
1.7  fold increased risk of first idiopathic VTE (van Hylckama Vlieg et al, 2007). The 
association between elevated thrombin generation and the risk of first VTE was confirmed 
in several other studies (Dargaud et al, 2006; Lutsey et al, 2009; Wichers et al, 2009). 
Furthermore, elevated thrombin generation identifies patients at risk of VTE recurrence. In 
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one cohort it was shown that patients with low levels of thrombin generation after 
discontinuation of anticoagulant treatment had an almost 60 % lower risk of recurrence 
compared to patients with elevated thrombin generation (Hron et al, 2006). Subsequent 
studies have confirmed that patients at high risk of VTE recurrence can be identified by 
TGA (Hron et al, 2006; Tripodi et al, 2008; Besser et al, 2008; Eichinger et al, 2008).   
Overall haemostasis potential (OHP) is based on repeated spectrophotometric registration 
of fibrin formation in two parallel samples of citrated plasma,  to which small amounts of 
thrombin and t-PA (the first plasma sample) or only thrombin (the second plasma sample) 
are added. The areas under the fibrin formation curves obtained represent OHP (the first 
plasma sample with thrombin and t-PA) and overall coagulation potential (OCP, the second 
plasma sample with only thrombin added). Overall fibrinolytic potential (OFP) is calculated 
as the difference between OHP and OCP (He et al, 2001). The OHP assay is not 
commercially available and it is not yet standardized. It is, however, inexpensive, easy and 
fast to perform (Antović, 2008).  
OHP has been shown to detect hypercoagulability in smaller studies. Increased OHP was 
found in 75 % of women with a history of pregnancy-provoked VTE. In women with 
concomitant TF (acquired activated protein C resistance or factor V Leiden) imbalance in 
haemostatic potential was more severe, since OHP was increased in all women (Antović et 
al, 2003). In another study, OHP also identified the hypercoagulable state in patients with 
lupus anticoagulants and a history of thrombotic events, regardless of concomitant 
anticoagulant therapy (Curnow et al, 2007). Using a modification of the original OHP assay 
(the coagulation inhibitor potential CIP assay), severe TF (deficiencies of antithrombin, 
protein C and protein S, homozygosity for factor V Leiden and combinations) could be 
detected with a sensitivity of 100 % and specificity of 70 - 80% (Andresen et al, 2002, 2004). 
OHP was also studied during anticoagulant treatment for VTE. In a study of 70 patients 
with acute venous thrombosis given standard anticoagulant treatment (low-molecular-
weight heparin followed by warfarin), OHP was significantly increased before treatment 
and greatly decreased during combined treatment with heparin and warfarin (overlapping 
period), while during warfarin only treatment OHP was about half that before treatment. 
After cessation of therapy, OHP values increased but remained lower than in the pre-
treatment period. OHP levels did not differ between patients with or without TF (Vižintin-
Cuderman et al, to be published).  
3.2 Specific markers of haemostasis activation  
F1+2 and TAT are markers of in vivo activity of factor X and thrombin. They are liberated 
during activation and generation of thrombin and are stable enough to be detected by 
laboratory methods, mainly enzyme-linked immunosorbent assays. However, they are 
extremely sensitive to in vitro artefacts. The quality of the sample and the reliability of the 
result depend on the technique of blood sampling and the experience of the person 
performing the procedure (Stegnar et al, 2007). Besides blood sampling, the different 
reagents used as well as the preparation and storage of the samples can influence the results 
(Greenberg et al 1994; Miller et al, 1995). Consequently, they are rarely used today. 
However, around twenty years ago they were tested in various small studies that gave 
contradictory results.  
Increased F1+2 was found in individuals with antithrombin, protein C and S deficiencies 
(Demers et al, 1992; Mannucci et al, 1992), as well as in those with activated protein C (APC) 
www.intechopen.com
 
Thrombophilia 
 
28
resistance (Simioni et al, 1996; Bauer et al, 2000), prothrombin G20210A mutation (Bauer et 
al, 2000) antiphospholipid syndrome (Ames et al, 1996), hyperhomocysteinemia (Kyrle et al, 
1997a) and increased levels of factor VIII (O’Donnell et al, 2001). Not all studies, however, 
confirmed the association of increased F1+2 levels with TF (Kyrle et al, 1998; Eichinger et al, 
1999; Lowe et al, 1999).  
TAT was increased in association with increased factor VIII levels (O’Donnell et al, 2001) 
and also with APC resistance in one study (Simioni et al, 1996), but not in two others 
(Eichinger et al, 1999; Lowe et al, 1999). Similarly, increased TAT was not associated with 
antithrombin (Demers et al, 1992), protein C and S deficiencies (Macherel et al, 1992) or with 
antiphospholipid syndrome (Ames et al, 1996). 
In patients with acute VTE, F1+2 and TAT are elevated and normalize 2 to 4 days after 
introduction of heparin treatment (The DVTENOX study group, 1993; Stricker et al, 1999; 
Peternel et al, 2000). The levels of these markers remain low also during treatment with 
warfarin (Elias et al, 1993; Jerkemann et al, 2000; Vižintin-Cuderman et al, to be published). 
TF does not seem to influence F1+2 and TAT levels either during anticoagulant treatment or 
after its withdrawal (Cuderman et al, 2007; Vižintin-Cuderman et al, to be published). 
There are few studies on the utility of these markers in assessing VTE recurrence risk. In two 
studies F1+2 was not associated with recurrence in patients with a history of VTE (Kyrle et 
al, 1997b, Vižintin-Cuderman et al, to be published). Two recent studies, however, showed 
that in patients with VTE increased F1+2 measured 1 month after withdrawal of 
anticoagulant treatment was associated with increased risk of recurrent thrombosis, 
irrespective of TF status (Poli, 2008, 2010). 
D-dimer is a degradation product of cross-linked fibrin. It is marker of both activated 
coagulation and fibrinolysis. D-dimer is best known today as the biochemical gold standard 
for initial assessment of suspected VTE.  It has a sensitivity of up to 95 % and a negative 
predictive value of nearly 100 % (Di Nisio et al, 2007) and is an integral part of diagnostic 
algorithms to exclude VTE (Righini et al, 2008). 
In patients with acute VTE, D-dimer is elevated and decreases after 1 to 3 days of treatment, 
but remains above normal levels for at least the first week of treatment (The DVTENOX 
study group, 1993; Stricker et al, 1999; Peternel et al, 2002). This is probably due to 
prolonged fibrinolysis, which is independent of heparin therapy and thrombin generation, 
but it may also be partly due to the relatively long half-life of D-dimer (Mannucci, 1994). By 
the first month of treatment, D-dimer levels mostly return to normal and remain so 
throughout warfarin treatment (Elias et al, 1993; Meissner et al, 2000; Vižintin-Cuderman et 
al, to be published).  One study showed that during anticoagulant treatment in patients with 
TF, D-dimer levels remain higher than in patients without TF, albeit not significantly 
(Vižintin-Cuderman et al, to be published). After discontinuation of anticoagulant 
treatment, D-dimer levels in patients with TF remain higher than in those without TF 
(Palareti et al, 2003, Vižintin-Cuderman et al, to be published). 
D-dimer was also investigated as a risk factor of the first VTE event and its recurrence. In a 
population-based cohort study, D-dimer was associated with a 3–fold increased risk of the 
first VTE event (Cushman et al, 2003) and with a 2.2 – 3–fold increased risk of recurrent VTE 
(Andreescu et al, 2002; Palareti et al, 2003: Cosmi et al, 2005). 
Moreover, D-dimer is a marker for predicting VTE recurrence after cessation of 
anticoagulant treatment (Verhovsek et al, 2008). Normal levels of D-dimer one month after 
cessation of anticoagulant treatment have been shown to have a high negative predictive 
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value for VTE recurrence (Palareti et al, 2002; Eichinger et al, 2003). These results were tested 
in an interventional study in patients with unprovoked VTE. It was shown that elevated D-
dimer one month after cessation of anticoagulant treatment significantly increases the risk of 
recurrent VTE, which can be reduced by resumption of anticoagulant therapy (Palareti et al, 
2006). Interestingly, it was demonstrated that in patients with TF who have elevated D-
dimer levels one month after cessation of anticoagulant treatment, the risk of recurrence is 
particularly high in comparison to patients with TF who have normal D-dimer. The 
difference was particularly important in carriers of common TF defects, such as factor V 
Leiden and prothrombin G20210A mutation (Palareti et al, 2003).   
Surprisingly, there are few studies on the association of D-dimer with specific TF defects. 
Elevated D-dimer was found in carriers of factor V Leiden (Eichinger et al, 1999, Cuderman 
et al, 2007) and in the presence of antiphospholipid antibodies (Ames et al, 1996).  
3.3 Markers of endothelial and platelet activation  
P-selectin is a cell adhesion molecule that is expressed by platelets and endothelial cells 
upon their activation and is partly released in plasma in its soluble form. It can be measured 
in plasma by an enzyme-linked immunosorbent assay.   
P-selectin levels are increased in acute VTE (Smith et al, 1999; Božič et al, 2002; Rectenwald 
et al, 2005; Ramacciotti et al, 2011). When P-selectin was tested as a possible marker for 
diagnosis of VTE, it was shown that a combination of the clinical prediction score and low 
P-selectin can be used to exclude VTE with a sensitivity and specificity similar to that of D-
dimer. In addition, the combination of the clinical prediction score and high P-selectin has, 
unlike D-dimer, a very high positive predictive value in confirming acute VTE (Rectenwald 
et al, 2005; Ramacciotti et al, 2011).  
After commencement of anticoagulant treatment for VTE, P-selectin levels decrease. A small 
study showed a decrease in P-selectin levels after 7 days of treatment with unfractionated 
heparin (Papalambros et al, 2004). In a study of 70 patients receiving low-molecular-weight 
heparin followed by warfarin, P-selectin levels decreased already after 3 days of treatment. 
Interestingly, one month after treatment discontinuation, P-selectin levels were not 
significantly higher than during treatment (Vižintin-Cuderman et al, to be published). 
Similarly, in another study there was no difference in P-selectin levels between patients 
receiving warfarin and those without anticoagulant therapy (Ay et al, 2007).  
In patients with a history of VTE, elevated P-selectin is associated with increased risk of 
recurrence. Two case-control studies found that in patients at least 3 months after the onset 
of acute VTE, P-selectin levels were elevated compared to healthy controls (Blann et al, 2000; 
Ay et al, 2007). This result was confirmed in two prospective cohort studies that investigated 
P-selectin as a predictive marker for recurrence in patients with VTE (Kyrle et al, 2007; 
Vižintin-Cuderman et al, to be published). Similarly in another prospective cohort study, 
elevated P-selectin was a predictor of the occurrence of VTE in cancer patients (Ay et al, 
2008).  
There is not much evidence, however, on P-selectin levels in relation to specific TF defects. 
In a small study it was shown that P-selectin is elevated in patients with lupus 
anticoagulants and a history of VTE (Bugert et al, 2007). The presence of TF did not 
influence P-selectin levels during and after anticoagulant treatment in another study 
(Vižintin-Cuderman et al, to be published).  Finally, TF status did not have any influence on 
P-selectin as a risk factor of VTE recurrence (Kyrle et al, 2007). 
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The association of other markers of endothelial and platelet activation (E-selectin, VCAM-
1, ICAM-1, t-PA and PAI-1) with TF and VTE is poorly investigated.  In a small study, E-
selectin, VCAM-1 and ICAM-1 were not shown to be elevated in acute VTE (Bucek et al, 
2003). However, elevated VCAM-1 levels were found in patients with acute VTE in two 
earlier studies (Smith et al, 1999, Božič et al, 2002). Elevated PAI-1 and t-PA levels were 
associated with increased risk of first or recurrent VTE in some studies (Schulman & 
Wiman, 1996; Meltzer et al, 2010), but not in others (Crowther et al, 2001; Folsom et al, 2003). 
The influence of TF on t-PA and PAI-1 levels was addressed in two small studies in patients 
with a history of VTE. No difference was found between patients with factor V Leiden 
(Stegnar et al, 1997) or hyperhomocysteinemia (Božič et al, 2000) and patients without these 
TF defects. 
4. Conclusions 
Assessment of haemostasis activation (hypercoagulability) is a very demanding task due to 
the complexity of the haemostatic system. However, it can be achieved either by global 
haemostasis screening assays that provide an overview of the entire haemostatic system, 
including enzymes, cofactors and inhibitors, or alternatively, by measuring specific 
haemostasis activation markers - peptides, enzymes or enzyme-inhibitor complexes that are 
liberated with the activation of coagulation,  fibrinolysis, endothelial cells and platelets in 
vivo.  Two global haemostasis screening assays (aPTT and TEG) have been used for many 
years, albeit their usefulness in detecting hypercoagulability and the risk of first and 
recurrent VTE seems to be limited due to insufficient clinical data, lack of standardization 
and the influence of pre-analytical factors. TGA and OHP are more promising. Both assays 
seem to be sensitive to TF defects and to be associated with the risk of VTE. Apart from D-
dimer, other specific haemostasis activation markers, namely F1+2 and TAT, are extremely 
sensitive to in vitro artefacts and are rarely used today. However, around twenty years ago 
they were tested in various small studies that gave contradictory results. D-dimer is more 
robust and clinically useful for excluding VTE and also for detecting the risk of VTE  after 
discontinuation of anticoagulant treatment.  The risk of recurrence seems to be particularly 
high in patients with common TF defects, such as factor V Leiden and prothrombin 
G20210A mutation and high D-dimer. Finally, it has been shown that P-selectin, a marker of 
endothelial and platelet activation, can be used to exclude VTE with sensitivity and 
specificity similar to that of D-dimer. However, there is not much evidence on the 
association of P-selectin with specific TF defects.  
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Thrombophilia(s) is a condition of increased tendency to form blood clots. This condition may be inherited or
acquired, and this is why the term is often used in plural. People who have thrombophilia are at greater risk of
having thromboembolic complications, such as deep venous thrombosis, pulmonary embolism or
cardiovascular complications, like stroke or myocardial infarction, nevertheless those complications are rare
and it is possible that those individuals will never encounter clotting problems in their whole life. The enhanced
blood coagulability is exacerbated under conditions of prolonged immobility, surgical interventions and most of
all during pregnancy and puerperium, and the use of estrogen contraception. This is the reason why many
obstetricians-gynecologysts became involved in this field aside the hematologists: women are more frequently
at risk. The availability of new lab tests for hereditary thrombophilia(s) has opened a new era with reflections
on epidemiology, primary healthcare, prevention and prophylaxis, so that thrombophilia is one of the hottest
topics in contemporary medicine.
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